Reduced-Antigen Combined Diphtheria-Tetanus-Acellular Pertussis Vaccine (Boostrix™)A Viewpoint by Pierre Van Damme, Marie Van der Wielen and Heidi Theeten

被引：0
|
作者：
Pierre Van Damme
Marie Van der Wielen
Heidi Theeten
机构：
[1] University of Antwerp,Centre for the Evaluation of Vaccination
来源：
Drugs | 2003年 / 63卷 / 13期
关键词：
D O I：
10.2165/00003495-200363130-00007
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1415 / 1416
页数：1
相关论文
共 37 条
  • [31] Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults
    Brandon, Donald
    Kimmel, Murray
    Kuriyakose, Sherine O.
    Kostanyan, Lusine
    Mesaros, Narcisa
    [J]. VACCINE, 2018, 36 (42) : 6325 - 6333
  • [32] Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine
    Kosuwon, P
    Warachit, B
    Hutagalung, Y
    Borkird, T
    Kosalaraksa, P
    Bock, HL
    Poovorawan, Y
    [J]. VACCINE, 2003, 21 (27-30) : 4194 - 4200
  • [33] Safety of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine when administered during pregnancy as part of the maternal immunization program in Brazil: a single center, observational, retrospective, cohort study
    Sancovski, Mauro
    Mesaros, Narcisa
    Feng, Yang
    Angeles Ceregido, M.
    Luyts, Dominique
    De Barros, Eliana
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (12) : 2873 - 2881
  • [34] Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults (vol 36, pg 6325, 2018)
    Brandon, Donald
    Kimmel, Murray
    Kuriyakose, Sherine O.
    Kostanyan, Lusine
    Mesaros, Narcisa
    [J]. VACCINE, 2020, 38 (12) : 2746 - 2747
  • [35] Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine A randomized, controlled trial in children primed according to a 2+1 schedule in infancy
    Ferrera, Giuseppe
    Cuccia, Mario
    Mereu, Gabriele
    Icardi, Giancarlo
    Bona, Gianni
    Esposito, Susanna
    Marchetti, Federico
    Messier, Marc
    Kuriyakose, Sherine
    Hardt, Karin
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (03)
  • [36] Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study
    Kovac, Martina
    Kostanyan, Lusine
    Mesaros, Narcisa
    Kuriyakose, Sherine
    Varman, Meera
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1977 - 1986
  • [37] A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK
    Marlow, Robin
    Kuriyakose, Sherine
    Mesaros, Narcisa
    Han, Htay Htay
    Tomlinson, Richard
    Faust, Saul N.
    Snape, Matthew D.
    Pollard, Andrew J.
    Finn, Adam
    [J]. VACCINE, 2018, 36 (17) : 2300 - 2306
1234